Engrave Wealth Partners LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,818 shares of the company’s stock after selling 1,742 shares during the quarter. Johnson & Johnson makes up about 1.5% of Engrave Wealth Partners LLC’s holdings, making the stock its 15th biggest position. Engrave Wealth Partners LLC’s holdings in Johnson & Johnson were worth $4,213,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Boston Trust Walden Corp raised its holdings in Johnson & Johnson by 8.2% in the 4th quarter. Boston Trust Walden Corp now owns 982,387 shares of the company’s stock valued at $173,539,000 after acquiring an additional 74,831 shares during the last quarter. Western Financial Corp CA acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $971,000. Gilman Hill Asset Management LLC boosted its position in Johnson & Johnson by 25.7% in the 4th quarter. Gilman Hill Asset Management LLC now owns 14,824 shares of the company’s stock valued at $2,619,000 after buying an additional 3,030 shares during the last quarter. Nvest Financial LLC boosted its holdings in Johnson & Johnson by 1.9% in the fourth quarter. Nvest Financial LLC now owns 18,555 shares of the company’s stock valued at $3,278,000 after purchasing an additional 338 shares during the last quarter. Finally, Hengehold Capital Management LLC boosted its stake in shares of Johnson & Johnson by 12.4% during the 4th quarter. Hengehold Capital Management LLC now owns 18,719 shares of the company’s stock valued at $3,307,000 after buying an additional 2,066 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Price Performance
Shares of JNJ opened at $155.00 on Friday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $186.69. The firm has a market cap of $403.66 billion, a PE ratio of 23.00, a PEG ratio of 2.64 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The firm’s 50 day moving average price is $158.02 and its 200 day moving average price is $167.12.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio is 67.06%.
Insider Activity at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.35% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. Piper Sandler decreased their target price on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 1st. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $173.67.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- Walmart Shares Jump on Evercore Analyst Upgrade
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
